ASH 2022 | The role of MRD status & the ELN 2022 in predicting clinical outcomes of patients with AML
Eunice Wang, MD, Roswell Park Comprehensive Cancer Centre, Buffalo, NY, discusses a retrospective analysis which evaluated the role of measurable residual disease (MRD) status and the new European LeukemiaNet (ELN) 2022 classification in predicting the outcomes of patients with acute myeloid leukemia (AML) treated with venetoclax and either azacitidine or decitabine. This interview took place at the 64th ASH Annual Meeting and Exposition congress held in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Genentech: Consultancy; Macrogenics: Consultancy; Daiichi Sankyo: Consultancy, Honoraria, Other: Advisory Board; Takeda: Consultancy, Honoraria, Other: Advisory Board; PTC Therapeutics: Consultancy, Honoraria, Other: Advisory Board; Rafael Pharmaceuticals: Other: Data Safety Monitoring Committee; Dava Oncology: Consultancy, Speakers Bureau; Gilead: Consultancy, Honoraria, Other: Advisory Board; Kite Pharmaceuticals: Consultancy, Honoraria, Other: Advisory Board; Novartis: Consultancy, Honoraria, Other: Advisory Board; GlaxoSmithKline: Consultancy, Honoraria, Other: Advisory Board; Mana Therapeutics: Consultancy, Honoraria; Abbvie: Consultancy, Honoraria, Other: member of data monitoring committee ; Kura Oncology: Consultancy, Honoraria, Other: Advisory Board, Steering Committee, Speakers Bureau; Stemline Therapeutics: Consultancy, Honoraria, Other: Advisory Board, Speakers Bureau; Astellas: Consultancy, Honoraria; Pfizer: Consultancy, Honoraria, Other: Advisory Board, Speakers Bureau; BMS/Celgene: Membership on an entity’s Board of Directors or advisory committees; Jazz Pharmaceuticals: Consultancy, Honoraria, Other: Advisory Board.
